September 7, 2021 - RNA Disease Diagnostics to disrupt and democratize molecular testing with POC and home-use focus

RNA Disease Diagnostics (RNADD) is positioning its Antisense Molecular Diagnostic Platform to disrupt diagnostic testing with a rapid, point-of-care (POC) molecular COVID-19 test at high-traffic locations, such as doctor’s offices, pharmacies, airports, restaurants and stadiums, and in homes, with near-term testing in labs.

Read MoreRead More
April 30, 2021

RNA-extraction-free nano-amplified colorimetric test for point-of-care clinical diagnosis of COVID-19

The global pandemic of coronavirus disease 2019 (COVID-19) highlights the shortcomings of the current testing paradigm for viral disease diagnostics. Here, we report a stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for rapid and naked-eye molecular diagnosis of COVID-19.

Read MoreRead More
October 20, 2020

Rapid, Ultrasensitive, and Quantitative Detection of SARS-CoV-2 Using Antisense Oligonucleotides Directed Electrochemical Biosensor Chip

The emergence of novel viruses has often ravaged humanity and thus marked its devastating footstep in the course of modern history. Viruses such as yellow fever, influenza H1N1, polio, human immune deficiency virus (HIV), severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) coronaviruses, Ebola, and Zika virus have led to pandemics, affecting health and the global economy.(1)

Read MoreRead More
May 21, 2020

Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles

An unexpected outbreak of coronavirus disease 2019 (COVID-19) has collapsed many health care systems and crashed numerous economies. The disease was first identified in December 2019 and has since rapidly spread across the world, resulting in the ongoing 2019–20 pandemic.(1)

Read MoreRead More